Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Karim Masri

Rheumatology Richmond, VA Medical Doctor

NPI 1336451038 CMS profile 332673

9602 Patterson Ave, Richmond, VA 23229

Open in the dashboard

General payments

$146,701

692 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Karim Masri of Richmond, VA is reported in the CMS Open Payments database as having received $146,701 across 692 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $271 10
2021 General $30,249 162
2020 General $51,293 230
2019 General $64,887 290

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karim Masri
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Karim Masri were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Karim Masri Rheumatology median Middle half National median
2019 $64,887 $744 $153–$2,687 $163
2020 $51,293 $462 $98–$2,027 $114
2021 $30,249 $531 $101–$2,153 $132
2022 $271 $627 $125–$2,303 $149
2023 $0 $741 $145–$2,524 $160
2024 $0 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Horizon Therapeutics plc $80,260 140 payments
  2. Pfizer Inc. $30,735 130 payments
  3. Lilly USA, LLC $19,164 77 payments
  4. Novartis Pharmaceuticals Corporation $10,512 39 payments
  5. Amgen Inc. $1,315 69 payments
  6. AbbVie, Inc. $1,206 63 payments
  7. Janssen Biotech, Inc. $483 28 payments
  8. Mallinckrodt Hospital Products Inc. $479 23 payments
  9. Celgene Corporation $355 11 payments
  10. Alexion Pharmaceuticals, Inc. $328 14 payments
  11. Other $1,862 98 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Honoraria $69,422 66 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $45,524 28 payments
  3. Travel and Lodging $16,777 63 payments
  4. Food and Beverage $11,731 531 payments
  5. Consulting Fee $3,150 1 payment
  6. Education $96 3 payments
Products named General payments · program years 2019–2022
  1. KRYSTEXXA $79,974 133 payments
  2. XELJANZ $30,477 117 payments
  3. TALTZ $17,505 47 payments
  4. COSENTYX Immunology $9,893 35 payments
  5. Prolia $593 38 payments
  6. COSENTYX Dermatology $551 1 payment
  7. HUMIRA $517 31 payments
  8. RINVOQ $481 24 payments
  9. ACTHAR $479 23 payments
  10. SIMPONI ARIA $431 23 payments
  11. Other $6,003 300 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

692 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record